Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-01-13
2009-12-15
Berch, Mark L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S279000, C544S091000, C544S229000, C546S309000
Reexamination Certificate
active
07632839
ABSTRACT:
The present invention relates to fluorinated aminoalkyl-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine derivatives that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
REFERENCES:
patent: 2005/0234080 (2005-10-01), Coleman et al.
Tao, et al., Mol. Cell. Biol. Doi:10.1128/MCB.01505-06, <http://mcb.asm.org/cgi/reprint/MCB.01505-06v1.pdf>, downloaded Oct. 9, 2008.
Cox, et al., Bioorganic & Medicinal Chemistry Letters, vol. 15, Issue 8, Apr. 15, 2005, pp. 2041-2045.
Sarli, et al., Cancer Drug Discovery & Development: Checkpoint Responses in Cancer Therapy, Humana Press, 2008, pp. 207-226.
Schmidt, et al., Drug Resistance Updates 10 (2007) 162-181.
Coleman Paul J.
Hartman George D.
Beeler Nicole M.
Berch Mark L
Jaisle Cecilia M
Merck & Co. , Inc.
Muthard David A.
LandOfFree
Mitotic kinesin inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mitotic kinesin inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mitotic kinesin inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4149563